论文部分内容阅读
本试验由许多医学中心参加,采用随机、双盲、安慰剂对照的方式,观察维拉帕米对急性心梗后死亡率及重大意外(死亡和再梗塞)发生率的影响。878例患者服用维拉帕米,剂量为360mg/d,897例服用安慰剂。入院后第二周开始用药,持续18个月(平均16个月)。在维拉帕米组和安慰剂组,分别有95例和119例死亡,分别有146例和180例发生重大意外。两组的18个月死亡率分别为11.1%和13.8%(P=0.11,危险比为0.80;95%可信限为0.61—1.05),18个月重大意外发生率分别为18%和21.6%(P=0.03,危险比为0.80;95%可信限为0.64—0.99)。改以冠心病监护病房内无心衰的患者为对象,维拉帕米组
This trial was attended by many medical centers in a randomized, double-blind, placebo-controlled manner to observe the effect of verapamil on the post-acute MI mortality and on major accidents (death and reinfarction). 878 patients took verapamil at a dose of 360 mg / day and 897 took placebo. The second week after admission medication, for 18 months (average 16 months). In the verapamil and placebo groups, 95 and 119 deaths occurred, with 146 and 180 major accidents, respectively. The 18-month mortality rates in both groups were 11.1% and 13.8% (P = 0.11, hazard ratio was 0.80; 95% confidence limit was 0.61-1.05). The 18-month major accident rates were 18% and 21.6% (P = 0.03, hazard ratio 0.80; 95% confidence limit 0.64-0.99). Change to coronary heart disease in patients with heart failure patients as the object, verapamil group